Inhibitory effects of rosiglitazone on lipopolysaccharide-induced inflammation in a murine model and HK-2 cells

American Journal of Nephrology

Volumn 34, Issue 2, 2011, Pages 152-162

  Wang, W M ^a   Chen, H ^a   Zhong, F ^a   Lu, Y ^a   Han, L ^a   Chen, N ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Lipopolysaccharide; Monocyte chemoattractant protein 1; Nuclear factor B; Peroxisome proliferator activated receptor ; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CREATININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SYNAPTOTAGMIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

ANILIDES; ANIMALS; BLOOD UREA NITROGEN; CHEMOKINE CCL2; CREATININE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; MICE; NF-KAPPA B; PPAR GAMMA; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 79959838099     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000329120     Document Type: Article

References (36)

1. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11: 152-176.
2. Sanz AB, Sanchez-Nino MD, Ramos AM: NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262.
3. Collins T, Cybulsky MI: NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis. J Clin Invest 2001; 107: 255-264
4. Rangan G, Wang Y, Harris D: NF-kappaB signalling in chronic kidney disease. Front Biosci 2009; 14: 3496-3522.
5. Wang Y, Rangan GK, Goodwin B: Lipopolysaccharide- induced MCP-1 gene expression in rat tubular epithelial cells is nuclear factor- kappaB dependent. Kidney Int 2000; 57: 2011-2022.
6. Viedt C, Orth SR: Monocyte chemoattractant protein-1 (MCP-1) in the kidney: Does it more than simply attract monocytes. Nephrol Dial Transplant 2002; 17: 2043-2047.
7. Rosen ED, Spiegelman BM: PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-37734.
8. Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
9. Guan Y, Zhang Y, Davis L, Breyer MD: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273:F1013-F1022.
10. Yang T, Michele DE, Park J: Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999; 277:F966-F973.
11. Rogler G: Significance of anti-inflammatory effects of PPARgamma agonists. Gut 2006; 55: 1067-1069.
12. Staels B, Fruchart JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005; 54: 2460-2470.
13. Zoico E, Garbin U, Olioso D: The effects of adiponectin on interleukin-6 and MCP-1 secretion in lipopolysaccharide-treated 3T3- L1 adipocytes: Role of the NF-kappaB pathway. Int J Mol Med 2009; 24: 847-851.
14. Mizgerd JP, Lupa MM, Spieker MS: NF-kappaB p50 facilitates neutrophil accumulation during LPS-induced pulmonary inflammation. BMC Immunol 2004; 5: 10.
15. Cuzzocrea S, Pisano B, Dugo L: Rosiglitazone, a ligand of the peroxisome proliferators- activated receptor-α, reduces acute inflammation. Eur J Pharmacol 2004; 483: 79-93.
16. Jiang C, Ting A, Seed B: PPAR agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
17. Imaizumi T, Matsumiya T, Tamo W: 15- Deoxy-D12,14-prostaglandin J 2 inhibits CX3CL1/fractalkine expression in human endothelial cells. Immunol Cell Biol 2002; 80: 531-536.
18. Lebovitz HE, Banerji MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-294.
19. Stolar MW, Chilton RJ: Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003; 25:B4-B31.
20. Nicholas SB, Kawano Y, Wakino S: Expression and function of peroxisome proliferator- activated receptor-gamma in mesangial cells. Hypertension 2001; 37: 722-727.
21. Zheng F, Fornoni A, Elliot SJ: Upregulation of type 1 collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002; 282:F639-F648.
22. Asano T, Wakisaka M, Yoshinari M: Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 2000; 1497: 148-154.
23. Gruden G, Setti G, Hayward A: Mechanical stretch induces monocyte chemoattrac-tant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: Inhibition by rosiglitazone. J Am Soc Nephrol 2005; 16: 688-696.
24. Zafiriou S, Stanners SR, Polhill TS: Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int 2004; 65: 1647-1653.
25. Panchapakesan U, Pollock CA, Chen XM: The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells. Am J Physiol Renal Physiol 2004; 287:F528-F534.
26. Lee S, Kim W, Moon SO: Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006; 21: 2096-2105.
27. Xiao J, Leung JC, Chan LY: Crosstalk between peroxisome proliferator-activated receptor- gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy. Clin Immunol 2009; 132: 266-276.
28. Liu HF, Guo LQ, Huang YY: Thiazolidinedione attenuate proteinuria and glomerulosclerosis in adriamycin-induced nephropathy rats via slit diaphragm protection. Nephrology (Carlton) 2010; 15: 75-83.
29. Efrati S, Berman S, Chachashvili A: Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction. Nephrology (Carlton) 2009; 14: 189-197.
30. Kiss E, Popovic ZV, Bedke J: Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage. Am J Pathol 2010; 176: 2150-2162.
31. Fujiwara K, Hayashi K, Ozawa Y: Renal protective effect of troglitazone in Wistar fatty rats. Metabolism 2000; 49: 1361-1364.
32. Isshiki K, Haneda M, Koya D: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulinsensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032.
33. Buckingham RE, Al-Barazanji KA, Toseland CD: Peroxisome proliferator-activated receptor- gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998; 47: 1326-1334.
34. Yoshida K, Kohzuki M, Xu HL: Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure. J Hypertens 2001; 19: 503-510.
35. Ma LJ, Marcantoni C, Linton MF: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910.
36. Pascual G, Fong AL, Ogawa S: A sumoylation- dependent pathway mediating transrepression of inflammatory response genes by PPAR Nature 2005; 437: 759-763.